ImmuPharma plc (LON:IMM – Get Free Report) traded down 11.4% during mid-day trading on Friday . The stock traded as low as GBX 2.71 ($0.03) and last traded at GBX 3.10 ($0.04). 30,011,082 shares changed hands during trading, an increase of 48% from the average session volume of 20,325,906 shares. The stock had previously closed at GBX 3.50 ($0.04).
ImmuPharma Stock Performance
The company has a market cap of £15.30 million, a PE ratio of -367.30 and a beta of 1.53. The firm’s 50 day moving average is GBX 1.44 and its 200-day moving average is GBX 1.65.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Articles
- Five stocks we like better than ImmuPharma
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Why Invest in 5G? How to Invest in 5G Stocks
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- 3 Best Fintech Stocks for a Portfolio Boost
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
